18 Works

Additional file 1 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 1: Table S1. Characteristics and outcome of patients presenting with cefoxitin-susceptible-ESBL-PE infections admitted in the ICU during the study period.

Additional file 5 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 5: Figure S3. Probability of target attainment for various cefoxitin doses in patients with CCRIBW = 100 ml/min.

Additional file 6 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 6: Figure S4. Probability of target attainment for different levels of renal function with a cefoxitin dose of 6g/day.

Additional file 3 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 3: Figure S1. Model prediction versus observed cefoxitin concentrations.

Additional file 4 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 4: Figure S2. Visual predictive check obtained with the final model.

Additional file 7 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 7: Table S3. Univariate factors associated with cefoxitin treatment failure.

Additional file 8 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 8: Table S4. Univariate factors associated with the acquisition of cefoxitin-resistance.

Additional file 1 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 1: Table S1. Characteristics and outcome of patients presenting with cefoxitin-susceptible-ESBL-PE infections admitted in the ICU during the study period.

Additional file 4 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 4: Figure S2. Visual predictive check obtained with the final model.

Additional file 5 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 5: Figure S3. Probability of target attainment for various cefoxitin doses in patients with CCRIBW = 100 ml/min.

Additional file 6 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 6: Figure S4. Probability of target attainment for different levels of renal function with a cefoxitin dose of 6g/day.

Additional file 1 of Adherence to opioid agonist therapy predicts uptake of direct-acting antivirals in people who use drugs: results from the French national healthcare database (the ANRS FANTASIO study)

Benjamin Rolland, Caroline Lions, Vincent Di Beo, Patrizia Carrieri, Nicolas Authier, Tangui Barré, Jessica Delorme, Philippe Mathurin, François Bailly, Camelia Protopopescu & Fabienne Marcellin
Additional file 1. STROBE Statement—Checklist of items that should be included in reports of cohort studies.

Additional file 1 of Adherence to opioid agonist therapy predicts uptake of direct-acting antivirals in people who use drugs: results from the French national healthcare database (the ANRS FANTASIO study)

Benjamin Rolland, Caroline Lions, Vincent Di Beo, Patrizia Carrieri, Nicolas Authier, Tangui Barré, Jessica Delorme, Philippe Mathurin, François Bailly, Camelia Protopopescu & Fabienne Marcellin
Additional file 1. STROBE Statement—Checklist of items that should be included in reports of cohort studies.

Additional file 2 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 2: Table S2. Population PK parameters of cefoxitin.

Additional file 2 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 2: Table S2. Population PK parameters of cefoxitin.

Additional file 3 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 3: Figure S1. Model prediction versus observed cefoxitin concentrations.

Additional file 7 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 7: Table S3. Univariate factors associated with cefoxitin treatment failure.

Additional file 8 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 8: Table S4. Univariate factors associated with the acquisition of cefoxitin-resistance.

Registration Year

  • 2022
    18

Resource Types

  • Text
    18

Affiliations

  • Hôpital de la Croix-Rousse
    18
  • Hospices Civils de Lyon
    18
  • University of Lyon System
    16
  • Centre Hospitalier Lyon Sud
    16
  • Centre Hospitalier Universitaire d'Angers
    16
  • Claude Bernard University Lyon 1
    16
  • Inserm
    16
  • Biometry and Evolutionary Biology Laboratory
    16
  • Air Liquide (France)
    16
  • University of Angers
    16